Table 1.
Characteristics of the study subjectsa
| Parameters | Hong Kong healthy volunteers | Danish patients |
|---|---|---|
| Age (years) | 48 ± 7 | 69 ± 9 |
| Current/former/never smokers | 9/9/82 | 5/7/25 |
| BMI (kg/m2) | 23.8 ± 2.7 | 28.7 ± 5.5 |
| Waist circumference (cm) | 82 ± 7 | — |
| Heart rate | 65 ± 8 | — |
| SBP (mmHg) | 117 ± 14 | 135 ± 21 |
| DBP (mmHg) | 74 ± 11 | 73 ± 13 |
| FBG (mmol/L) | 5.8 ± 0.7 | — |
| Triglycerides (mmol/L) | 1.7 ± 0.8 | 1.4 ± 0.6 |
| TC (mmol/L) | 5.4 ± 0.9 | 3.8 ± 0.9 |
| HDL (mmol/L) | 1.6 ± 0.2 | 1.1 ± 0.4 |
| LDL (mmol/L) | 3.5 ± 0.9 | 2.1 ± 0.9 |
| Plasma creatinine (μmol/L) | 52.5 ± 9.6 | 94.6 ± 30.1 |
| Plasma hsCRP (mg/L) | 2.1 (1.0–7.5) | 3.9 (1.8–8.4) |
| Plasma FGF21 (ng/L) | 81.7 (30.4–138.6) | 134.2 (52.9–225.9) |
| Anti‐hypertensive drugs | — | 78.3% |
| Statins | — | 56.7% |
| Anti‐diabetic drugs | — | 29.7% |
| Left ventricular ejection fraction | — | 53 ± 8% |
DBP, diastolic blood pressure; FBG, fasting blood glucose; FGF21, fibroblast growth factor 21.
a
Data are shown as means ± SD or median (interquartile range) when not normally distributed.